Gyre Therapeutics (GYRE) Current Deferred Revenue (2010 - 2025)
Gyre Therapeutics (GYRE) reported Current Deferred Revenue of $14000.0 for Q4 2025, down 77.05% year-over-year from $61000.0 in Q4 2024, and down 75.86% on a QoQ basis from $58000.0 in Q3 2025.
Gyre Therapeutics (GYRE) has 15 years of Current Deferred Revenue data on file, last reported at $14000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 77.05% year-over-year to $14000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14000.0 (down 77.05% YoY) and the FY2025 annual result came in at $14000.0, down 77.05% from the prior year.
- Current Deferred Revenue retreated to $14000.0 in Q4 2025 per GYRE's latest filing, from $58000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $2.0 million in Q2 2021 and bottomed at $14000.0 in Q4 2025.
- The 5-year median for Current Deferred Revenue is $58000.0 (2025), against an average of $378923.1.
- Peak annual rise in Current Deferred Revenue reached 517.58% in 2021, while the deepest fall reached 88.4% in 2021.
- Tracing GYRE's Current Deferred Revenue over 5 years: stood at $230000.0 in 2021, then slumped by 36.96% to $145000.0 in 2022, then slumped by 73.1% to $39000.0 in 2023, then surged by 56.41% to $61000.0 in 2024, then sank by 77.05% to $14000.0 in 2025.
- Per Business Quant, the three latest GYRE Current Deferred Revenue figures stand at $14000.0 (Q4 2025), $58000.0 (Q3 2025), and $28000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 58,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 35,000.00 |
| Dec 31, 2023 | 39,000.00 |
| Dec 31, 2022 | 145,000.00 |
| Dec 31, 2021 | 230,000.00 |
| Sep 30, 2021 | 853,000.00 |
| Jun 30, 2021 | 2.04 Mn |
| Mar 31, 2021 | 1.33 Mn |
| Dec 31, 2020 | 1.98 Mn |
| Sep 30, 2020 | 764,000.00 |
| Jun 30, 2020 | 330,000.00 |
| Dec 31, 2019 | 15.00 Mn |
| Dec 31, 2018 | 15,000.00 |
| Sep 30, 2018 | 13,000.00 |
| Jun 30, 2018 | 10,000.00 |
| Dec 31, 2017 | 7,000.00 |
| Sep 30, 2017 | 18,000.00 |
| Jun 30, 2017 | 29,000.00 |
| Mar 31, 2017 | 40,000.00 |
| Dec 31, 2016 | 283,000.00 |
| Sep 30, 2016 | 401,000.00 |
| Jun 30, 2016 | 500,000.00 |
| Mar 31, 2016 | 600,000.00 |
| Dec 31, 2015 | 19,000.00 |
| Sep 30, 2015 | 438,000.00 |
| Dec 31, 2014 | 26,000.00 |
| Jun 30, 2014 | 25,000.00 |
| Mar 31, 2014 | 61,000.00 |
| Dec 31, 2012 | 2.36 Mn |
| Sep 30, 2012 | 2.36 Mn |
| Jun 30, 2012 | 4.86 Mn |
| Mar 31, 2012 | 35.92 Mn |
| Dec 31, 2011 | 57.71 Mn |
| Sep 30, 2011 | 74.45 Mn |
| Jun 30, 2011 | 73.49 Mn |
| Dec 31, 2010 | 81.71 Mn |